User profiles for Christopher S. Coffey

Christopher S. Coffey

Professor of Biostatistics, University of Iowa
Verified email at uiowa.edu
Cited by 19681

[PDF][PDF] AHA/ASA Guideline

WJ Powers, CP Derdeyn, J Biller, CS Coffey, BL Hoh… - Stroke, 2015 - ergjax.com
Purpose—The aim of this guideline is to provide a focused update of the current recommendations
for the endovascular treatment of acute ischemic stroke. Where there is overlap, the …

Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management …

…, RP Frantz, AJ Foreman, CS Coffey… - Circulation, 2010 - Am Heart Assoc
Background— Factors that determine survival in pulmonary arterial hypertension (PAH) drive
clinical management. A quantitative survival prediction tool has not been established for …

2015 American Heart Association/American Stroke Association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke …

WJ Powers, CP Derdeyn, J Biller, CS Coffey, BL Hoh… - Stroke, 2015 - Am Heart Assoc
Purpose— The aim of this guideline is to provide a focused update of the current recommendations
for the endovascular treatment of acute ischemic stroke. When there is overlap, the …

β-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction

DT Ko, PR Hebert, CS Coffey, A Sedrakyan, JP Curtis… - Jama, 2002 - jamanetwork.com
Contextβ-Blocker therapy remains substantially underused in cardiac patients despite its
proven mortality benefits. Reluctance to prescribe these agents may derive from concerns …

Very early hypothermia induction in patients with severe brain injury (the National Acute Brain Injury Study: Hypothermia II): a randomised trial

…, D Zygun, CS Coffey, P Drever, S Fourwinds… - The Lancet …, 2011 - thelancet.com
Background The inconsistent effect of hypothermia treatment on severe brain injury in
previous trials might be because hypothermia was induced too late after injury. We aimed to …

Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study

…, R Kurth, C Caspell-Garcia, CS Coffey… - The Lancet …, 2023 - thelancet.com
Background Emerging evidence shows that α-synuclein seed amplification assays (SAAs)
have the potential to differentiate people with Parkinson's disease from healthy controls. We …

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease

…, CS Coffey, T Waligórska, P Taylor, S Pan… - JAMA …, 2013 - jamanetwork.com
Importance We observed a significant correlation between cerebrospinal fluid (CSF) levels
of tau proteins and α-synuclein, but not β-amyloid 1-42 (Aβ1-42), and lower concentration of …

The Parkinson's progression markers initiative (PPMI)–establishing a PD biomarker cohort

…, A Siderowf, S Lasch, CS Coffey… - Annals of clinical …, 2018 - Wiley Online Library
Christopher S. Coffey served as a consultant receiving consulting fees from The Michael J.
Fox Foundation for Parkinson's Research; Received research funding from NINDS, NHLBI, …

[HTML][HTML] Trial of amitriptyline, topiramate, and placebo for pediatric migraine

SW Powers, CS Coffey, LA Chamberlin… - … England Journal of …, 2017 - Mass Medical Soc
Background Which medication, if any, to use to prevent the headache of pediatric migraine
has not been established. Methods We conducted a randomized, double-blind, placebo-…

Natural history of infantile‐onset spinal muscular atrophy

SJ Kolb, CS Coffey, JW Yankey… - Annals of …, 2017 - Wiley Online Library
Objective Infantile‐onset spinal muscular atrophy (SMA) is the most common genetic cause
of infant mortality, typically resulting in death preceding age 2. Clinical trials in this …